ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 272,32
-0,03%
Dow Jones
42 780,36
-0,14%
DAX
19 848,77
-0,34%
Brent Oil
72,15
-0,78%
Bitcoin
93 301,04
-1,90%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ACELYRIN Inc (SLRN)

  7. ACELYRIN Inc (SLRN) Actualités

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SLRN
DateHeureSourceTitreSymboleSociété
10/12/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
10/12/202422h30GlobeNewswire Inc.ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of UveitisNASDAQ:SLRNACELYRIN Inc
13/11/202423h26Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SLRNACELYRIN Inc
13/11/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
13/11/202422h00GlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SLRNACELYRIN Inc
06/11/202422h00GlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024NASDAQ:SLRNACELYRIN Inc
04/11/202422h11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
16/10/202413h00GlobeNewswire Inc.ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
19/09/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024NASDAQ:SLRNACELYRIN Inc
10/09/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive SurNASDAQ:SLRNACELYRIN Inc
22/08/202413h00GlobeNewswire Inc.ACELYRIN, INC. to Participate in Upcoming Investor ConferencesNASDAQ:SLRNACELYRIN Inc
13/08/202422h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial ResultsNASDAQ:SLRNACELYRIN Inc
06/08/202422h30GlobeNewswire Inc.ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024NASDAQ:SLRNACELYRIN Inc
05/06/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
29/05/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
25/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
18/05/202401h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
09/05/202414h14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
09/05/202414h01GlobeNewswire Inc.ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesNASDAQ:SLRNACELYRIN Inc
09/05/202414h00GlobeNewswire Inc.ACELYRIN, INC. Announces Leadership TransitionNASDAQ:SLRNACELYRIN Inc
29/04/202422h05GlobeNewswire Inc.ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024NASDAQ:SLRNACELYRIN Inc
28/03/202421h05GlobeNewswire Inc.ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
27/03/202421h01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:SLRNACELYRIN Inc
20/03/202412h00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
11/03/202413h02GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisNASDAQ:SLRNACELYRIN Inc
11/03/202413h00GlobeNewswire Inc.ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsNASDAQ:SLRNACELYRIN Inc
15/02/202422h05GlobeNewswire Inc.ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsNASDAQ:SLRNACELYRIN Inc
12/01/202411h45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
20/12/202322h30GlobeNewswire Inc.ACELYRIN, INC. Appoints Lynn Tetrault to Board of DirectorsNASDAQ:SLRNACELYRIN Inc
 Showing the most relevant articles for your search:NASDAQ:SLRN

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
LR
Legrand
NYSE
NKE
Nike
EU
AF
Air FranceKLM
NYSE
KO
Coca Cola
EU
GLE
Societe Generale
COIN
BTCUSD
Bitcoin
EU
CS
Axa
COIN
AVAXUSD
Avalanche
COIN
XRPUSD
Ripple
NASDAQ
AAPL
Apple
FTSE
UKX
FTSE 100
EU
RNO
Renault
COIN
ADAUSD
Cardano
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés